You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

Optimizing the Use of BTK Inhibitors in CLL: Skills Challenge and Clinical Pearls

  • Authors: Jackie Broadway, DNP, RN, FNP-BC
  • CE Released: 6/5/2020
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 6/5/2021
Start Activity


Target Audience and Goal Statement

This activity is intended for oncology nurses and oncology nurse practitioners.

 

The goal of this activity is to improve oncology nurses' and nurse practitioners' knowledge about of the role of Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL), to improve their skills in managing treatment-related adverse events, and to improve their skills in counseling patients regarding their CLL treatment.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of BTK inhibitors in the treatment of CLL
    • Potential adverse events (AEs) of available BTK inhibitors
  • Have greater competence related to
    • Managing treatment-related AEs of BTK inhibitors
  • Have increased confidence in their ability to
    • Provide education to patients receiving BTK inhibitors


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Jackie Broadway, DNP, APRN, FNP-BC

    Family Nurse Practitioner
    Department of Leukemia
    The University of Texas
    MD Anderson Cancer Center
    Adjunct Faculty
    Department of Leukemia
    The University of Texas
    Cizik School of Nursing
    Houston, Texas

    Disclosures

    Disclosure: Jackie Broadway, DNP, RN, FNP-BC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals; Genentech Biomedical

Steering Committee

  • John M. Pagel, MD, PhD

    Chief of Hematologic Malignancies
    Director of Hematopoietic Stem Cell Transplantation Program
    Center for Blood Disorders and Stem Cell Transplantation
    Swedish Cancer Institute
    Seattle, Washington

    Disclosures

    Disclosure: John M. Pagel, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Gilead Sciences, Inc.; Pharmacyclics, Inc.

  • Danielle M. Brander, MD

    Assistant Professor of Medicine
    Director, CLL & Lymphoma Clinical Research Program
    Duke University Medical Center
    Durham, North Carolina

    Disclosures

    Disclosure: Danielle M. Brander, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; AstraZeneca; Genentech Pharmaceuticals; Novartis, Inc.; TG Therapeutics, Inc.
    Received grants for clinical research from: AbbVie; BeiGene (Beijing) Co., Ltd; DTRM; Genentech Pharmaceuticals; MEI Pharma
    Other: Novartis-DSMB

  • Jan A. Burger, MD, PhD

    Professor of Medicine
    Department of Leukemia
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Disclosure: Jan A. Burger, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Janssen Pharmaceuticals
    Served as a speaker or a member of a speakers bureau for: Gilead Sciences, Inc.; Janssen Pharmaceuticals; Novartis; TG Therapeutics, Inc.; Pharmacyclics, Inc.
    Received grants for clinical research from: BeiGene (Beijing) Co., Ltd; Gilead Sciences, Inc.; Pharmacyclics, Inc.; TG Therapeutics, Inc.

  • Anthony R. Mato, MD, MSCE

    Director, Chronic Lymphocytic Leukemia Program
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Disclosure: Anthony R. Mato, MD, MSCE, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pharmacyclics, Inc.; TG Therapeutics, Inc.
    Received grants for clinical research from: AbbVie Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Loxo Oncology; Sunesis Pharmaceuticals, Inc.; Pharmacyclics, Inc.; TG Therapeutics, Inc.

  • Jeff Sharman, MD

    Director of Research
    Willamette Valley Cancer Institute
    Medical Director of Hematology Research
    US Oncology Network
    Eugene, Oregon

    Disclosures

    Disclosure: Jeff Sharman, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Acerta Pharma, LLC; AstraZeneca; Genentech Pharmaceuticals; Sunesis Pharmaceuticals, Inc.; Pharmacyclics, Inc.

  • Deborah Stephens, DO

    Assistant Professor
    Division of Hematology and Hematologic Malignancies
    University of Utah
    Huntsman Cancer Institute
    Salt Lake City, Utah

    Disclosures

    Disclosure: Deborah Stevens, DO, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Acerta Pharma, LLC; Gilead Sciences, Inc.; Karyopharm Therapeutics

Editor

  • Mindy Tanzola, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Mindy Tanzola,PhD, has disclosed no relevant financial relationships.

CE Reviewer

  • Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

    Associate Director, Accreditation and Compliance , Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

Optimizing the Use of BTK Inhibitors in CLL: Skills Challenge and Clinical Pearls

Authors: Jackie Broadway, DNP, RN, FNP-BCFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 6/5/2020

Valid for credit through: 6/5/2021

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print